PFM
VYGR icon

Privium Fund Management’s Voyager Therapeutics VYGR Stock Holding History

Privium Fund Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Hold
120,000
– – 0.08% 59
2026
Q1 		$463K Buy
120,000
+25,000
+26% +$98.4K 0.1% 55
2025
Q4 		$373K Buy
95,000
+50,000
+111% +$221K 0.07% 51
2025
Q3 		$210K Buy
45,000
+19,759
+78% +$71.5K 0.04% 59
2025
Q2 		$78.8K Buy
25,241
+3,596
+17% +$11.6K 0.02% 55
2025
Q1 		$73.2K Buy
+21,645
New +$101K 0.02% 56

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Privium Fund Management's VYGR Position: Q2 2026 in Review

Privium Fund Management held its Voyager Therapeutics (VYGR) position steady in Q2 2026 at 120,000 shares worth $420K. The position accounts for 0.08% of the portfolio, ranked #59.

Privium Fund Management first reported a position in VYGR in Q1 2025 and has held it in 6 quarters since. The position peaked at $463K in Q1 2026. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Privium Fund Management held 120,000 shares of Voyager Therapeutics worth $420K as of Q2 2026.
  • Privium Fund Management left its Voyager Therapeutics share count unchanged in Q2 2026.
  • Voyager Therapeutics made up 0.08% of Privium Fund Management's portfolio in Q2 2026, its #59 holding.
  • Privium Fund Management first reported a position in Voyager Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Privium Fund Management's Voyager Therapeutics position peaked at $463K in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.